News & Updates

Nonsmall cell lung cancer (NSCLC) patients with high PD-L1 expression appear to show a strong preference for receiving atezolizumab subcutaneously rather than intravenously.

Use of anlotinib combined with etoposide and carboplatin (EC; chemotherapy) as first-line therapy for patients with extensive-stage small cell lung cancer (ES-SCLC) yields a significantly improved progression-free survival (PFS) as well as overall survival (OS) benefits when compared with chemotherapy, according to data from the phase III ETER701 trial presented at ELCC 2024.

A recent study has shown the benefits of salt substitution in reducing all-cause or cardiovascular (CV) mortality. However, the evidence remains unclear as regards lowering CV events and not increasing serious adverse events, specifically in a Western population.

A local study has raised concerns about a high rate of hypovitaminosis D in early pregnancy in Singapore.

Progressive resistant training (PRT) does not seem to work better than neuromuscular exercise (NEMEX) for easing hip pain and improving functional performance or hip-related quality of life (QoL) in patients with hip osteoarthritis (OA), reports a recent study.

Treatment with amivantamab (ami) in combination with chemotherapy (chemo) results in substantially longer time to treatment discontinuation (TTD), time to subsequent therapy (TTST), and progression-free survival (PFS) after first subsequent therapy (PFS2) in patients with EGFR-mutant advanced nonsmall cell lung cancer (NSCLC) following progression on osimertinib, as shown in a postprogression analysis.